Humira (adalimumab) has potential interactions with several other drugs. For example, taking prednisone with Humira can increase the risk of side effects from both drugs. Humira may also interact with ...

The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...

After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs... Blockbuster drug Humira finally faces lower-cost ...

MedImpact Healthcare Systems, an independent provider of health solutions, technology and pharmacy benefit services, is expanding access to Humira biosimilars, Simlandi and adalimumab-adaz, for new ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

(Reuters) - Amgen Inc's version of AbbVie Inc's Humira arthritis drug, the world's top-selling medicine, appears similar in potency and safety to the original product, U.S. Food and Drug ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. In a unique legal challenge, the Dutch Pharmaceutical ...